71.35
前日終値:
$70.72
開ける:
$71
24時間の取引高:
818.02K
Relative Volume:
0.77
時価総額:
$2.41B
収益:
$55.63M
当期純損益:
$-158.10M
株価収益率:
-8.4737
EPS:
-8.4202
ネットキャッシュフロー:
$-203.94M
1週間 パフォーマンス:
+10.04%
1か月 パフォーマンス:
+12.10%
6か月 パフォーマンス:
+87.62%
1年 パフォーマンス:
+185.40%
Nektar Therapeutics Stock (NKTR) Company Profile
名前
Nektar Therapeutics
セクター
電話
(415) 482-5300
住所
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Compare NKTR vs VRTX, REGN, ARGX, RVMD, ALNY
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
NKTR
Nektar Therapeutics
|
71.35 | 2.39B | 55.63M | -158.10M | -203.94M | -8.4202 |
|
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
|
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-24 | 開始されました | Wedbush | Neutral |
| 2026-03-17 | 開始されました | TD Cowen | Buy |
| 2026-02-10 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2025-11-26 | 開始されました | Citigroup | Buy |
| 2025-06-24 | 繰り返されました | BTIG Research | Buy |
| 2025-06-24 | 繰り返されました | H.C. Wainwright | Buy |
| 2025-04-11 | アップグレード | Jefferies | Hold → Buy |
| 2025-03-14 | アップグレード | Oppenheimer | Perform → Outperform |
| 2025-01-08 | 開始されました | B. Riley Securities | Buy |
| 2024-12-10 | 開始されました | H.C. Wainwright | Buy |
| 2024-11-04 | 開始されました | Piper Sandler | Overweight |
| 2024-09-30 | 再開されました | BTIG Research | Buy |
| 2024-06-28 | 開始されました | Rodman & Renshaw | Buy |
| 2023-11-20 | 再開されました | JP Morgan | Underweight |
| 2023-11-09 | アップグレード | TD Cowen | Market Perform → Outperform |
| 2023-05-10 | アップグレード | Jefferies | Underperform → Hold |
| 2023-02-24 | ダウングレード | Jefferies | Hold → Underperform |
| 2022-08-08 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2022-05-31 | 再開されました | Jefferies | Hold |
| 2022-04-18 | ダウングレード | Goldman | Neutral → Sell |
| 2022-03-15 | ダウングレード | Cowen | Outperform → Market Perform |
| 2022-03-15 | ダウングレード | Mizuho | Buy → Neutral |
| 2022-03-14 | ダウングレード | BTIG Research | Buy → Neutral |
| 2022-03-14 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-03-14 | ダウングレード | Stifel | Buy → Hold |
| 2022-03-14 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2022-03-09 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-11-08 | アップグレード | The Benchmark Company | Hold → Buy |
| 2021-09-10 | 開始されました | BofA Securities | Neutral |
| 2021-06-28 | アップグレード | Stifel | Hold → Buy |
| 2021-05-18 | 再開されました | Goldman | Neutral |
| 2021-02-22 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2021-01-06 | 開始されました | Stifel | Hold |
| 2020-09-14 | 開始されました | JP Morgan | Neutral |
| 2020-06-10 | ダウングレード | CFRA | Hold → Sell |
| 2020-05-12 | 繰り返されました | H.C. Wainwright | Neutral |
| 2020-04-22 | 開始されました | The Benchmark Company | Buy |
| 2020-03-30 | アップグレード | Goldman | Sell → Neutral |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2020-02-03 | アップグレード | Mizuho | Neutral → Buy |
| 2019-10-24 | 開始されました | Oppenheimer | Perform |
| 2019-10-08 | ダウングレード | Goldman | Buy → Sell |
| 2019-08-09 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-08-09 | ダウングレード | Jefferies | Buy → Hold |
| 2019-08-09 | ダウングレード | Mizuho | Buy → Neutral |
| 2019-03-15 | 開始されました | SVB Leerink | Mkt Perform |
| 2018-12-13 | 開始されました | Goldman | Buy |
| 2018-06-11 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2018-06-04 | 繰り返されました | H.C. Wainwright | Buy |
| 2018-04-20 | 開始されました | Seaport Global Securities | Buy |
| 2018-04-13 | 再開されました | Piper Jaffray | Overweight |
| 2018-04-06 | 繰り返されました | Mizuho | Buy |
| 2018-04-02 | 再開されました | H.C. Wainwright | Buy |
すべてを表示
Nektar Therapeutics (NKTR) 最新ニュース
Is Nektar Therapeutics (NKTR) Undervalued On Its Phase 3 Rezpegaldesleukin Launch? - simplywall.st
Nektar: Sanofi’s Exit Clears A Competitor But Raises The Bar In Atopic Dermatitis (NKTR) - Seeking Alpha
Nektar Therapeutics (NKTR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Stockholders to Connect - ACCESS Newswire
Nektar Therapeutics (NKTR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Nektar Therapeutics (NKTR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
NKTR|Nektar Therapeutics|Price:70.004|Chg%:-0.721 - TradingKey
Nektar Therapeutics (NKTR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Form 4 Nektar Therapeutics For: 24 July By Investing.com - Investing.com Nigeria
Nektar Therapeutics (NKTR) CEO granted 57,200 options with $15.15 strike - Stock Titan
Nektar Therapeutics Reports Vesting of 16,500 Stock Options for Chief R&D Officer Jonathan Zalevsky - Kalkine Media
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
How Investors Are Reacting To Nektar Therapeutics (NKTR) Launching Global Phase 3 ZENITH AD Trials - simplywall.st
ITH0.F interactive stock chart | Nektar Therapeutics R stock - Yahoo Finance UK
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Helus Pharma (HELP) and Nektar Therapeutics (NKTR) - The Globe and Mail
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nektar Therapeutics (NKTR) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
NKTR Stock Soars After Nektar Reports Positive Atopic Dermatitis Trial Results - Stocktwits
symbol__ Stock Quote Price and Forecast - CNN
NKTR|Nektar Therapeutics|Price:70.780|Chg%:+1.420 - TradingKey
Nektar Therapeutics Initiated at Buy by Canaccord Genuity - Moomoo
NKTR Up on Start of Phase III Program on Rezpeg for Atopic Dermatitis - Yahoo Finance
Nektar Therapeutics (NKTR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Nektar (NKTR) Launches Global Trials for Novel Atopic Dermatitis Treatment - GuruFocus
Nektar Therapeutics Starts Phase 3 ZENITH AD Program Evaluating Rezpegaldesleukin in Moderate-to-Severe AD - The Dermatology Digest
Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics (NKTR) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Enterprise value to EBIT forward of Nektar Therapeutics – BMV:NKTR - TradingView
Nektar Therapeutics (NKTR) Stock Looks Above Fair Value Despite Its 7x Run - simplywall.st
Enterprise value to EBITDA forward of Nektar Therapeutics – BMV:NKTR - TradingView
Price to sales forward of Nektar Therapeutics – BMV:NKTR - TradingView
Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Shareholders to Connect - ACCESS Newswire
ETFs Investing in Nektar Therapeutics Stocks - TradingView
Enterprise value to EBIT forward of Nektar Therapeutics – MUN:ITH0 - TradingView
Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Investors to Connect - ACCESS Newswire
2026-07-16 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Shareholders to Connect | NDAQ:NKTR | Press Release - Stockhouse
Nektar Therapeutics (NKTR) Investigation: Bronstein, Gewirtz & Gr - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics - The National Law Review
BTIG Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $178 - 富途牛牛
Q32 bounces back to claim study success for alopecia drug - BioPharma Dive
Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics (NKTR) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
2026-07-12 | Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics (NKTR) Stockholders to Inquire about Securities Investigation | NDAQ:NKTR | Press Release - Stockhouse
Does Nektar Therapeutics (NKTR) Straddling Russell Growth and Value Indexes Reveal a Conflicted Narrative? - Sahm
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nektar Therapeutics (NKTR) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Nektar Therapeutics (NKTR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Enterprise value to EBITDA forward of Nektar Therapeutics – LSE:0UNL - TradingView
Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS) and Nektar Therapeutics (NKTR) - The Globe and Mail
Nektar Therapeutics (NKTR) Advances Autoimmune Pipeline, Is The Upside Already Priced In? - simplywall.st
NKTR Stock Clocks Best Day In Over 2 Months As Investors Await Upcoming Clinical Data In Eczema - Stocktwits
Insider Sell: Jonathan Zalevsky Sells Shares of Nektar Therapeutics (NKTR) - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nektar Therapeutics (NKTR) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Nektar Therapeutics (NKTR) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):